ZMC(SH:600216)2022-10-26 16:00Financial Performance - The company's operating revenue for Q3 2022 was ¥2,006,205,112.46, a decrease of 8.56% compared to the same period last year[7]. - The net profit attributable to shareholders for Q3 2022 was ¥93,866,572.27, down 61.37% year-on-year[7]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥57,410,371.09, a decline of 70.88% compared to the previous year[7]. - The basic earnings per share for Q3 2022 was ¥0.10, reflecting a decrease of 60.00% year-on-year[10]. - The diluted earnings per share for Q3 2022 was also ¥0.10, down 60.00% from the same period last year[10]. - Total operating revenue for the first three quarters of 2022 was CNY 6,123,873,142.30, a decrease of 10.1% compared to CNY 6,811,651,988.14 in the same period of 2021[30]. - Net profit for the third quarter of 2022 was CNY 357,899,312.31, a decline of 47.8% from CNY 685,910,072.56 in the same quarter of 2021[33]. - Total comprehensive income for the period attributable to the parent company was CNY 482,860,926.55, down from CNY 742,419,297.12 in the same period last year, representing a decrease of approximately 34.9%[35]. - Basic and diluted earnings per share were both CNY 0.51, compared to CNY 0.78 in the previous year, reflecting a decline of 34.6%[35]. Cash Flow and Liquidity - The net cash flow from operating activities for the year-to-date was ¥141,215,952.32, a decrease of 68.84% compared to the previous year[10]. - Cash inflow from operating activities totaled CNY 6,410,825,337.82, down from CNY 7,051,753,669.29, a decline of approximately 9.1%[39]. - Cash outflow from operating activities was CNY 6,269,609,385.50, compared to CNY 6,598,619,416.76 in the previous year, showing a decrease of about 5%[39]. - The ending cash and cash equivalents balance was CNY 1,304,784,270.68, down from CNY 1,632,665,283.12, reflecting a decrease of approximately 20%[41]. - The company reported a tax refund of CNY 321,071,190.31, compared to CNY 213,805,121.98 in the previous year, marking an increase of about 50.1%[39]. Assets and Liabilities - Total assets at the end of the reporting period were ¥12,370,875,396.96, a decrease of 1.29% from the end of the previous year[10]. - The company's current assets totaled CNY 5,658,885,465.86, down from CNY 6,034,823,006.11, indicating a decrease of about 6.19%[25]. - Cash and cash equivalents were reported at CNY 1,304,784,270.68, a significant decrease from CNY 1,768,531,510.26, reflecting a decline of approximately 26.30%[21]. - The company's total liabilities decreased to CNY 5,658,885,465.86 from CNY 6,034,823,006.11, indicating a decline of approximately 6.19%[25]. - The company's total liabilities decreased to CNY 2,707,415,382.53 from CNY 3,349,948,357.08, indicating a reduction of 19.2%[28]. - The total equity attributable to shareholders increased to CNY 9,165,509,080.53, up from CNY 8,779,106,085.10, representing a growth of 4.4%[28]. - The minority interest increased to CNY 497,950,933.90 from CNY 402,925,398.05, reflecting a growth of 23.5%[30]. - The company's deferred income tax liabilities decreased to CNY 10,998,703.64 from CNY 20,830,017.00, a reduction of 47.3%[28]. Research and Development - The company reported a significant increase in new drug R&D expenses during the quarter, contributing to the decline in net profit[14]. - Research and development expenses for the first three quarters of 2022 were CNY 555,393,836.63, down 19.8% from CNY 692,647,517.23 in the same period of 2021[30]. - The company has no significant new product launches or technological developments reported during the quarter[19]. Operational Costs - Total operating costs for the first three quarters of 2022 were CNY 5,498,607,942.85, down from CNY 5,966,861,959.15, reflecting a reduction of 7.8%[30]. - The company reported a financial expense of CNY -37,178,071.08, compared to CNY 51,751,856.25 in the previous year, indicating a significant improvement[30].